Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Lindsey E. Carlasare joins Ethics Talk to discuss her article, coauthored with Dr Gerald B. Hickson: “Whose Responsibility Is It to Address Bullying in Health Care?”
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
The AMA’s Historic Health Fraud and Alternative Medicine Collection includes images of quack devices from the early 20th century that generated oversight we now take for granted.
AMA J Ethics. 2021;23(9):E721-738. doi:
10.1001/amajethics.2021.721.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.